secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001933414-23-000054
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys Therapeutics Q2 net loss $12.1M; cash $282.8M; Advance-HTN enrollment on track
--------------------------------------------------------------------------------

- Net loss of $12.1M for Q2 2023 vs $6.5M in Q2 2022, driven by increased R&D and G&A spend.
- Cash, equivalents and investments $282.8M as of June 30, 2023, up from $110.1M at Dec 31, 2022.
- R&D expenses $11.9M vs $5.6M YoY, reflecting initiation of lorundrostat pivotal program.
- Advance-HTN Phase 2 trial enrollment ongoing; topline data expected 1H 2024.
- Phase 3 Launch-HTN trial and Phase 2 CKD trial both expected to start in 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341423000054/0001933414-23-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341423000054/mlys-20230807.htm
  HTML page:      https://secwatch.observer/filing/0001933414-23-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer